探讨MRI联合乳腺钼靶X线诊断乳腺导管原位癌的应用价值。

选择2018年2月至2019年2月收治的90例乳腺导管原位癌患者，对所有患者给予乳腺钼靶X线及MRI检查，比较联合检查与单一检查的诊断价值。采用SPSS22.0进行统计分析，年龄和病灶直径计量资料采用(±s)表示，t检验；将病理诊断作为金标准，分析MRI及联合诊断的敏感度及特异度。计数资料采用n(%)表示，χ²检验，P<0.05为差异有统计学意义。

90例乳腺导管原位癌患者均为单发病灶，恶性病灶48例，良性病灶42例。恶性病灶患者的年龄与良性病灶差异无统计学意义(P>0.05)，良性病灶肿瘤直径低于恶性病灶(P<0.05)。将病理诊断结果作为金标准，MRI联合乳腺钼靶X线诊断的灵敏度和特异度分别为91.67%和90.48%，均高于单纯MRI的75.00%和71.43%及单纯乳腺钼靶的66.67%和64.29%%，差异有统计学意义(P<0.05)。

MRI联合乳腺钼靶X线在诊断乳腺导管原位癌时具有较高灵敏度和特异度，可为临床诊断及判断提供科学依据。

To investigate the clinical value of MRI combined with mammography in the diagnosis of mammary ductal carcinoma in situ.

From February 2018 to February 2019, 90 patients with mammary ductal carcinoma in situ were enrolled in to present study. All the patients received both mammography and MRI examinations of the mammary gland, and the diagnostic value of combined examinations was evaluated. Statistical analysis were performed by using SPSS 22.0 software. Measurement data such as age and lesion diameter were expressed as (±s) and were examined by using t test. Pathological diagnosis was used as the gold standard to analyze the sensitivity and specificity of MRI and combined diagnosis. Count data were expressed as n(%), and were examined by using χ² test, A P value <0.05 was considered as statistically significant.

All of 90 patients with breast ductal carcinoma in situ had a single lesion, including 48 malignant lesions, and 42 benign lesions. There was no significant difference of age between patients with malignant lesions and benign lesions (P>0.05). The diameter of benign lesions was lower than that of malignant lesions, with significant difference (P<0.05). Taking the pathological diagnosis results as the gold standard, the sensitivity and specificity of MRI combined with mammography mammography targets were 91.67% and 90.48% respectively, which were higher than 75.00% and 71.43% of MRI alone and 66.67% and 64.29 of mammography alone respectively, with significant difference (P<0.05).

MRI combined with mammography has high sensitivity and specificity in the diagnosis of mammary ductal carcinoma in situ, which could provide scientific basis for clinical diagnosis and judgment.